echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Immunology News > Four innovative drugs including the first TYK2 inhibitor are expected to be approved by the FDA in September

    Four innovative drugs including the first TYK2 inhibitor are expected to be approved by the FDA in September

    • Last Update: 2022-09-08
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ▎Edited by WuXi AppTec Content Team


    In September, the FDA is expected to make approval decisions on the following four drugs, detailed in the table below


    ▲New drugs that are expected to be approved in the United States in September (drawing by WuXi AppTec’s content team, click to see a larger image)


    Company Name: Spectrum Pharmaceuticals

    Indications: Chemotherapy-induced neutropenia




    Drug name: futibatinib

    Company Name: Taiho Oncology

    Indications: locally advanced or metastatic cholangiocarcinoma

    Taiho Oncology's futibatinib, a selective irreversible oral small molecule inhibitor of FGFR1, 2, 3, and 4, is seeking FDA approval for the treatment of patients with FGFR2 gene rearrangements (including gene fusions) ) in previously treated patients with locally advanced or metastatic cholangiocarcinoma



    Learn more about FDA-approved new drugs

    Please click the image below or scan the QR code to visit our applet




    ▲If you have any business needs, please long press to scan the QR code above, or

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.